Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
WWW.PRICINGPLATFORM.EU
EPP Life Sciences Executive Briefing
March 31, 2016
WWW.PRICINGPLATFORM.EU
EPP Life Sciences Briefing
An exclusive invitation-only event
• A unique opportunity to find and di...
WWW.PRICINGPLATFORM.EU
Warm Welcome from Our Moderator
Neil Grubert
Independent Global Market Access Consultant
• 26 years...
WWW.PRICINGPLATFORM.EU
Please, no ring tones
During the presentations:
ASK QUESTIONS FOR
BETTER INSIGHTS
After the present...
Pharma faces a perfect storm—high-profile criticism in the runup to an election
European politicians want greater international cooperation on pricing
Organisation of market access varies enormously
Source: Have You Optimized Your Market Access Efforts?
Level 1 Level 2 Lev...
Better internal organisation of market access remains a high priority
6,8
10,8
14,9
18,9
23,4
23,4
29,7
36,5
40,5
47,3
0 1...
WWW.PRICINGPLATFORM.EU
Programme for the Day
08:30-09:00 Welcome
09:00-09:15 Opening Comments | Neil Grubert
09:15-10:00 D...
WWW.PRICINGPLATFORM.EU
Programme for the Day
10:45-12:00 Shaping Up for the Future: A Vision of
the Future of Strategic Pr...
Upcoming SlideShare
Loading in …5
×

Neil Grubert's introduction to the EPP Life Sciences Executive Briefing

The European Pricing Platform (EPP) is the number one pricing knowledge sharing platform in Europe.

  • Be the first to comment

  • Be the first to like this

Neil Grubert's introduction to the EPP Life Sciences Executive Briefing

  1. 1. WWW.PRICINGPLATFORM.EU EPP Life Sciences Executive Briefing March 31, 2016
  2. 2. WWW.PRICINGPLATFORM.EU EPP Life Sciences Briefing An exclusive invitation-only event • A unique opportunity to find and discuss best practices and how these might apply to your current or future pricing organisation. • Promoting dialogue between senior managers and industry pricing and profit optimisation experts on emerging pricing and commercial topics. • Topics discussed will drive the 6th EPP Life Sciences Forum 2016 (September 20-21, 2016) and various industry activities.
  3. 3. WWW.PRICINGPLATFORM.EU Warm Welcome from Our Moderator Neil Grubert Independent Global Market Access Consultant • 26 years’ experience tracking the global prescription drug and self-medication markets. • Spearheaded the development of Decision Resources Group’s international market access business, most recently as Vice President of Global Market Access Insights. • Author of more than 150 reports on market access in 20 countries.
  4. 4. WWW.PRICINGPLATFORM.EU Please, no ring tones During the presentations: ASK QUESTIONS FOR BETTER INSIGHTS After the presentations: DISCUSS/SHARE YOUR OWN EXPERIENCES Margethe Vestager Respect the EPP code of conduct
  5. 5. Pharma faces a perfect storm—high-profile criticism in the runup to an election
  6. 6. European politicians want greater international cooperation on pricing
  7. 7. Organisation of market access varies enormously Source: Have You Optimized Your Market Access Efforts? Level 1 Level 2 Level 3 What market access includes Health economics and outcomes research (HEOR) HEOR integrated with pricing and reimbursement HEOR, healthcare systems intelligence and monitoring, tendering and innovative contracting, scenario modelling, real-world data generation, health policy and patient advocacy How market access is structured Under regulatory or corporate affairs, with a strong focus on technical aspects Under marketing, with a focus on therapeutic area Under the broader umbrella of commercial operations (possibly as an independent unit), with a marketing focus When market access is involved in the product life cycle Phase III, but especially pre-launch and in the commercialisation phase Phase IIb and III Target selection and pre-clinical identification Where the main responsibilities lie Mainly global Global with regional support and facilitating the development of local capabilities Fully fledged global, regional and local market access organisation with clear division of responsibilities Who implements the market access strategy at local level Sales reps, sometimes accompanied by marketing or medical team members Account managers (sales reps with enhanced market access knowledge/skills) Market access account manager in collaboration with other functions (integrated approach) • A 2011 survey by Executive Insight found that big pharma companies were generally much more sophisticated than mid-sized pharma or biotech companies with regard to the organisation of market access. Status observed in biotech and mid-sized pharma companies Status observed in big pharma companies
  8. 8. Better internal organisation of market access remains a high priority 6,8 10,8 14,9 18,9 23,4 23,4 29,7 36,5 40,5 47,3 0 10 20 30 40 50 Other More support from senior management Assistance in dealing with payers Assistance with differing regional access needs Better internal communication across business functions Improving internal skill sets Better sources of data Better operational integration between departments Clearer external guidelines by payers Earlier implementation of your market access strategy Solutions to Internal Market Access Challenges Based on a 2015 survey of 133 pharma, biotech, medtech and diagnostics executives in the US and Europe. Source: Quintiles-sponsored survey conducted by the Economist Intelligence Unit.
  9. 9. WWW.PRICINGPLATFORM.EU Programme for the Day 08:30-09:00 Welcome 09:00-09:15 Opening Comments | Neil Grubert 09:15-10:00 Darwin’s Medicine: the Evolution of the Life Sciences Industry and the Implications for Market Access and Pricing Capabilities | Prof. Brian D. Smith 10:00-10:30 Time to Reflect 10:30-10:45 Coffee Break
  10. 10. WWW.PRICINGPLATFORM.EU Programme for the Day 10:45-12:00 Shaping Up for the Future: A Vision of the Future of Strategic Pricing & Profit Optimisation Capabilities | Prof. Dr Florian Turk 12:00-12:15 Coffee Break 12:15-12:45 What Keeps Us Awake at Night? | Alan Crowther 12:45-13:00 Closing Remarks from Our Moderator Programme organised by EPP in collaboration with the Founding Partner for Life Sciences activities, Alliance Life Sciences

×